When neonatal mice are treated with antibodies to neutralize TSLP, IL-33 or their target expressed on DCs, OX40L, the ability of early RSV infection to prime pathological Th2 responses upon re-infection of adults is reduced (138, 145). The gene discussed is TSLP; the disease is infection.